Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion.
To test the hypothesis that a statin could reduce the recurrence rate of atrial fibrillation after electrical cardioversion (EC), we performed an open, controlled multicenter study. Patients (n = 114) who had atrial fibrillation >48 hours and who were scheduled for EC were randomized to receive 40 mg of pravastatin once daily for 3 weeks before and 6 weeks after EC or no drug in addition to standard therapy. Pravastatin did not reduce the recurrence rate of atrial fibrillation after EC.
Tveit
Arnljot
A
Department of Internal Medicine, Asker & Baerum Hospital, Rud, Norway. arnljot.tveit@broadpark.no
Grundtvig
Morten
M
Gundersen
Torstein
T
Vanberg
Paul
P
Semb
Anne Grete
AG
Holt
Even
E
Gullestad
Lars
L
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001281:Atrial Fibrillation / Q000517:prevention & control* / Q000628:therapy; D004334:Drug Administration Schedule; D004554:Electric Countershock; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009664:Norway; D017035:Pravastatin / Q000008:administration & dosage / Q000627:therapeutic use*; D055502:Secondary Prevention; D016896:Treatment Outcome
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D017035:Pravastatin